Clinical trial · Observational
Studying Malnutrition And Sarcopenia In Older Adults With Acute Myeloid Leukemia
Investigating The Prognostic Significance Of Malnutrition And Sarcopenia In Older Adults With Acute Myeloid Leukemia
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will explore how malnutrition (poor nutrition/diet) and sarcopenia (a condition that causes a loss of muscle and bone mass) affects study participants over the age of 60 with acute myeloid leukemia (AML) who will receive induction chemotherapy (chemotherapy given as the first treatment to help cancer go into remission) and/or cancer drugs as part of standard care for AML. By studying how these nutritional and skeletal factors, doctors leading this study hope to learn how malnutrition and sarcopenia may be able to predict certain outcomes --such as how long study participants with poor nutrition and muscle loss can live after chemotherapy- for older (age 60+) individuals with AML.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
| Leukemia, Myeloid | Myeloid Leukemia | ALIAS | 0.90 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 6 Minute Walk Test | Other | — | UNRESOLVED |
| Bioelectrical Impedence Analysis Device | Device | — | UNRESOLVED |
| Blood Test/Blood Draw | Diagnostic Test | — | UNRESOLVED |
| Computed Tomography Scans to Measure Skeletal Muscular Index | Diagnostic Test | — | UNRESOLVED |
| Hand Grip Strength Test | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Adults (age 60+) with Newly Diagnosed AML
- description
- This group will consist of participants age 60+ who will be assessed for malnutrition and sarcopenia. Participants in this group will undergo chemotherapy and/or receive cancer drugs (as part of standard care). Participants in this group will receive different assessments when they start induction therapy to measure their nutritional health and the severity of their sarcopenia.
- interventionNames
- Device: Bioelectrical Impedence Analysis Device
- Other: 6 Minute Walk Test
- Diagnostic Test: Computed Tomography Scans to Measure Skeletal Muscular Index
- Diagnostic Test: Blood Test/Blood Draw
- Other: Hand Grip Strength Test
- label
- Healthy Control Group: Adults with AML (age 60+) in Good Health
- description
- This group will also consist of participants age 60+ who will be assessed for malnutrition and sarcopenia. Participants in this group will undergo induction therapy and/or receive cancer drugs to treat their AML (as part of standard care). Participants in this group will also receive different assessments when they start induction therapy to measure their nutritional health and the severity of their sarcopenia. Participants in this group will receive the same assessment as participants in the first study group -- the only difference is that participants in this group have been determined to be healthier than those in the first study group according to clinical assessments.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Older Adult patients (greater than or equal to 60 years of age) * New diagnosis of acute myeloid leukemia (AML) * Receiving induction therapy (intensive or low intensity therapy) * Willing and able to provide written informed consent Exclusion Criteria: * Presence of a pacemaker or defibrillator. * Participants who are pregnant at the time of enrollment. * Anyone unable/unwilling to follow protocol requirements
References
Publications (0)
Data not yet available